Video wird geladen...
Video konnte nicht geladen werden
Learn more about Signatera and the foundational technology that is transforming care for patients with cancer. Hear directly from Natera CEO Steve Chapman on how Signatera can detect molecular residual disease and help determine whether therapy is working. #CancerCare #Signatera #MRD #Oncology #Natera
84,651 Aufrufe • vor 1 Jahr •via X (Twitter)
1 Kommentare

Randy Holcombevor 1 Jahr
@SteveChapmanCEO In a case of post op colo-rectal cancer, what does it mean when CEA starts going up but Signatera is negative?







